Payment overview · 2025
General Payments
$557.19
27 reported records · 16 companies
Healthcare provider profile · identity verified
Bradley Hunter Barrett, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NEODESHA, KS · NPI 1093781775
Verified facts
What the public records show
CMS Open Payments records show Bradley Hunter Barrett, M.D. received $557.19 in general payments during 2025 across 27 reported records.
Smith+Nephew, Inc. accounted for 16.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $90.57 | 16.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $58.79 | 10.6% | 4 | 2025 |
| BioWound Solutions, Inc. | Unresolved — no canonical attribution shown | $58.72 | 10.5% | 2 | 2025 |
| Reapplix Inc. | Unresolved — no canonical attribution shown | $56.75 | 10.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $53.74 | 9.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.35 | 6.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.83 | 6.6% | 2 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $25.52 | 4.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.15 | 4.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.71 | 3.9% | 1 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $21.49 | 3.9% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $18.24 | 3.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.18 | 2.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.39 | 2.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.80 | 2.5% | 1 | 2025 |
| Musculoskeletal Transplant Foundation Inc. | Unresolved — no canonical attribution shown | $8.96 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $557.19 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| bio-ConneKt Normalized: bio connekt |
Device | BioWound Solutions, Inc. | $58.72 | 2 | 2025 |
Source payment records
|
|||||
| 3C Patch Kit - Box Normalized: 3c patch kit box |
Device | Reapplix Inc. | $56.75 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $53.74 | 3 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $47.90 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $37.35 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $36.83 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.65 | 2 | 2025 |
Source payment records
|
|||||
| INNOVAMATRIX AC Normalized: innovamatrix ac |
Device | ConvaTec Inc. | $25.52 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| RENASYS GO v2 HOME Normalized: renasys go v2 home |
Device | Smith+Nephew, Inc. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 64 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
57 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 480 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 284 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 264 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 251 | 55 |
| Alprazolam | Alprazolam | 239 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 223 | 41 |
| Oxycodone Hcl | Oxycodone Hcl | 218 | 25 |
| Lisinopril | Lisinopril | 193 | 36 |
| Gabapentin | Gabapentin | 190 | 38 |
| Potassium Chloride | Potassium Chloride | 180 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 153 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 149 | 22 |
| Tramadol Hcl | Tramadol Hcl | 147 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 30 |
| Omeprazole | Omeprazole | 127 | 28 |
| Trazodone Hcl | Trazodone Hcl | 126 | 24 |
| Furosemide | Furosemide | 123 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 115 | 20 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 113 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 19 |
| Metformin Hcl | Metformin Hcl | 106 | 24 |
| Losartan Potassium | Losartan Potassium | 105 | 25 |
| Pregabalin | Pregabalin | 97 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 93 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 17 |
| Januvia | Sitagliptin Phosphate | 86 | 11 |
| Montelukast Sodium | Montelukast Sodium | 86 | 13 |
| Prednisone | Prednisone | 84 | 54 |
| Eliquis | Apixaban | 83 | 15 |
| Morphine Sulfate Er | Morphine Sulfate | 81 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 67 | 12 |
| Cephalexin | Cephalexin | 65 | 49 |
| Meloxicam | Meloxicam | 65 | 15 |
| Lorazepam | Lorazepam | 64 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 64 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | suppressed |
| Azithromycin | Azithromycin | 62 | 38 |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 15 |
| Finasteride | Finasteride | 59 | 13 |
| Farxiga | Dapagliflozin Propanediol | 57 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 13 |
| Amoxicillin | Amoxicillin | 56 | 39 |
| Estradiol | Estradiol | 55 | 12 |
| Mounjaro | Tirzepatide | 55 | suppressed |
| Ezetimibe | Ezetimibe | 54 | suppressed |
| Ondansetron Odt | Ondansetron | 53 | 18 |
| Carvedilol | Carvedilol | 51 | suppressed |
| Celecoxib | Celecoxib | 51 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 48 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 15 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Allopurinol | Allopurinol | 44 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Digoxin | Digoxin | 39 | suppressed |
| Topiramate | Topiramate | 39 | suppressed |
| Jardiance | Empagliflozin | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Fluconazole | Fluconazole | 36 | 22 |
| Gentamicin Sulfate | Gentamicin Sulfate | 35 | 25 |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Simvastatin | Simvastatin | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 33 | 11 |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 23 |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Torsemide | Torsemide | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 21 |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 13 |
| Ozempic | Semaglutide | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Nystatin | Nystatin | 21 | 15 |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 11 |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 18 | suppressed |
| Movantik | Naloxegol Oxalate | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Jantoven | Warfarin Sodium | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Sulindac | Sulindac | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $557.19 · 27 records | Smith+Nephew, Inc. | 3C Patch Kit - Box, AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, COLLAGENASE SANTYL, Cologuard Collection Kit, DALVANCE, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, ENFLONSIA, EVENITY, GARDASIL 9, GRAFIX PL, INNOVAMATRIX AC, Omnipod, PROLIA, PURAPLY WOUND MATRIX, RENASYS GO v2 HOME, TRELEGY ELLIPTA, VAXNEUVANCE, Wegovy, bio-ConneKt | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error